Product Details
Treatment with the 150-mg twice daily dose of dabigatran etexilate (Pradaxa, Boehringer Ingelheim) is equally safe and effective in patients with permanent, persistent, and paroxysmal atrial fibrillation, according to a new subgroup analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. The results were presented at the American College of Cardiology (ACC) 2011 Scientific Sessions last week.
Buy Now
Featured Product
Beniprime 8mg Tab
Benidipine 4 MG
